Management changes at Vifor Pharma

Swiss drugmaker Vifor Pharma (VTX: VIFN) today announced changes to its senior management team.

Barbara Angehrn joins the executive committee in the newly-created position of chief business Officer, effective November 1. Scott Garland has decided to step down as president of Vifor’s subsidiary Relypsa to pursue new opportunities in the biotech sector. Patrick Treanor has assumed the role on an interim basis.

Ms Angehrn brings extensive international experience in product in-licensing and commercialization, particularly in Europe and the US, having worked at Stepstone Pharma, Exelixis, Onyx and Amgen. Up until recently she has led a start-up focused on in-licensing speciality pharma products for the European market. She advised a number of pharmaceutical companies on their commercialization and market access strategies and has been working closely with Vifor Pharma over the last year. In her new role, Ms Angehrn will be responsible for the company's product pipeline, market access and rare diseases business.